Tofacitinib, marketed as Xeljanz and Xeljanz XR, is a Janus kinase (JAK) inhibitor used to treat certain types of inflammatory arthritis, including rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis [1].
How much does Tofacitinib cost?
The price of tofacitinib can vary significantly depending on factors such as dosage, quantity, insurance coverage, and the pharmacy. Without insurance, a 30-day supply of 5 mg tablets can range from approximately $3,000 to over $6,000 [2]. For example, Xeljanz 11 mg extended-release tablets (28 tablets) can cost around $1,500 to $2,000 without insurance [2].
Are there Tofacitinib savings programs available?
Pharmaceutical manufacturers often offer savings programs and copay assistance for their brand-name drugs. For Xeljanz, Pfizer offers a savings card that can reduce out-of-pocket costs for eligible patients with commercial insurance [3]. Patients are encouraged to check the official Xeljanz website or contact Pfizer directly for current program details and eligibility requirements [3].
When does the Tofacitinib patent expire?
The patent protection for tofacitinib has a complex timeline involving multiple patents. Some patents related to the drug's composition and use have expired or are nearing expiration in various regions. For instance, the primary composition of matter patent for tofacitinib in the United States was set to expire in 2028, but secondary patents and evergreening efforts can extend market exclusivity [4]. DrugPatentWatch.com tracks these patent expirations, noting that the key patent for tofacitinib is expected to expire around 2028, opening the door for generic versions [4].
Can generic versions of Tofacitinib be available?
Yes, generic versions of tofacitinib can become available once the relevant patents expire and regulatory approval is granted. The entry of generic competitors typically leads to a significant reduction in drug prices. DrugPatentWatch.com monitors patent landscapes to predict when generic alternatives may enter the market [4].
How does Tofacitinib compare to other arthritis treatments?
Tofacitinib is a targeted synthetic disease-modifying antirheumatic drug (DMARD). It works by inhibiting JAK enzymes, which play a role in the inflammatory pathways of various autoimmune diseases [1]. Other classes of treatments for inflammatory arthritis include traditional synthetic DMARDs (like methotrexate), other targeted synthetic DMARDs (like other JAK inhibitors), and biologic DMARDs (like TNF inhibitors) [5]. The choice of treatment depends on the specific condition, disease severity, patient history, and individual response to therapy.
What are the potential risks and side effects of Tofacitinib?
Tofacitinib carries boxed warnings due to an increased risk of serious infections, blood clots, stroke, heart attack, and certain cancers [1]. Common side effects can include upper respiratory tract infections, headache, diarrhea, and increased levels of certain liver enzymes [1]. Patients should discuss all potential risks and side effects with their healthcare provider before starting treatment.